ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
December 16, 2019
3 min watch
Save

VIDEO: Serum protein changes indicate response to siltuximab in Castleman disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO — Researchers identified proteins that began to change within 8 days of initiating siltuximab in patients with idiopathic multicentric Castleman disease, a rare immune system disorder, according to a video interview at ASH Annual Meeting & Exposition.

David C. Fajgenbaum, MD, of the University of Pennsylvania and the Castleman Disease Collaborative Network, and colleagues examined serum proteomic changes disease to help clinicians indicate the patients who were likely to respond and those not likely to respond to siltuximab.

“It’s really important to make progress for Castleman disease, but we also realize this is an opportunity to make progress for other rare diseases more generally and as a model for rare disease research,” Fajgenbaum said.

Disclosure: Fajgenbaum reports research funding from Janssen Pharmaceuticals.